Abrilumab information

Abrilumab
Monoclonal antibody
Type	?
Source	Human
Target	integrin alpha-4 beta-7
Clinical data
Other names	AMG 181
ATC code	none;
Identifiers
CAS Number	1342290-43-0;
ChemSpider	none;
UNII	Y9UQ37XT2T;
KEGG	D10540;
Chemical and physical data
Formula	C6362H9806N1686O2014S52
Molar mass	143803.34 g·mol−1

Abrilumab (INN;^[1] development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.^[2]

This drug was developed by MedImmune.

^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Abrilumab, American Medical Association.

[1] World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Abrilumab, American Medical Association.

Abrilumab information

and 3 Related for: Abrilumab information

Abrilumab

Theralizumab

Spartalizumab